Acceleron Pharma (XLRN) Tops Q3 EPS by 3c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acceleron Reports Third Quarter 2018 Operating and Financial Results
October 30, 2018 4:05 PM EDTMEDALIST and BELIEVE Phase 3 trial results in myelodysplastic syndromes (MDS) and beta-thalassemia, respectively, are expected to be presented at the 60th American Society of Hematology (ASH) Annual Meeting
COMMANDS Phase 3 trial in patients with lower-risk MDS who are treatment naïve has been initiated
Part 1 results from the ACE-083 Phase 2 trial in facioscapulohumeral muscular dystrophy (FSHD) and Charcot-Marie-Tooth disease (CMT) were presented at the World Muscle Society Annual Meeting
Pulmonary Arterial Hypertension (PAH) R&D Deep Dive Event scheduled for Friday, November 16th in... More
